Tevogen Bio Holdings Inc. (TVGN)

USD 1.01

(3.23%)

Market Cap (In USD)

185.73 Million

Revenue (In USD)

-

Net Income (In USD)

-67.32 Thousand

Avg. Volume

964.88 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.256-21.09
PE
-14.43
EPS
-0.07
Beta Value
-1.029
ISIN
US88165K1016
CUSIP
-
CIK
1860871
Shares
183893430.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ryan H. Saadi M.D., M.P.H, M.P.H.
Employee Count
-
Website
https://tevogen.com
Ipo Date
2022-01-05
Details
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.